Patents by Inventor Gregory T. Bleck

Gregory T. Bleck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multifunctional protein molecules comprising decorin and use thereof
    Patent number: 11879009
    Abstract: The present invention relates to multifunctional protein molecules comprising decorin and uses thereof. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody and methods of their production and uses thereof.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: January 23, 2024
    Assignee: CATALENT PHARMA SOLUTIONS, LLC
    Inventor: Gregory T. Bleck
  • CELL LINES WITH MULTIPLE DOCKS FOR GENE INSERTION
    Publication number: 20230227858
    Abstract: The present invention relates to host cell lines containing multiple dock sites for insertion of a nucleic acid construct, and in particular nucleic acid constructs that express an exogenous gene of interest.
    Type: Application
    Filed: June 2, 2021
    Publication date: July 20, 2023
    Inventors: Gregory T. Bleck, Rachel H. Kravitz, Chad A. Hall
  • NUCLEIC ACID CONSTRUCTS FOR PROTEIN MANUFACTURE
    Publication number: 20230212590
    Abstract: The present invention relates to nucleic acid constructs and their use to develop host cell lines for production of a protein of interest, and in particular to nucleic acid constructs which allow for improved selection to develop high-producing cell lines.
    Type: Application
    Filed: June 2, 2021
    Publication date: July 6, 2023
    Inventors: Gregory T. Bleck, Rachel H. Kravitz, Chad A. Hall
  • MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF
    Publication number: 20220275074
    Abstract: The present invention relates to multifunctional protein molecules comprising decorin and uses thereof. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody and methods of their production and uses thereof.
    Type: Application
    Filed: May 6, 2022
    Publication date: September 1, 2022
    Inventor: Gregory T. Bleck
  • Multifunctional protein molecules comprising decorin and use thereof
    Patent number: 11377488
    Abstract: The present invention relates to multifunctional protein molecules comprising decorin and uses thereof. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody and methods of their production and uses thereof.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: July 5, 2022
    Assignee: CATALENT PHARMA SOLUTIONS, LLC
    Inventor: Gregory T. Bleck
  • DECORIN COMPOSITIONS AND USE THEREOF
    Publication number: 20220073579
    Abstract: The present invention relates to improved decorin compositions and methods of their production.
    Type: Application
    Filed: July 2, 2021
    Publication date: March 10, 2022
    Inventors: Gregory T. Bleck, Ian John Collins, Mark Joseph Frey
  • VECTORS FOR PROTEIN MANUFACTURE
    Publication number: 20220056476
    Abstract: The present invention relates to vectors and their use to develop host cell lines for production of a protein of interest, and in particular to vectors which utilize a weak promoter to drive a selectable marker.
    Type: Application
    Filed: December 4, 2019
    Publication date: February 24, 2022
    Inventors: Gregory T. Bleck, Rachel H. Kravitz, Chad A. Hall
  • MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF
    Publication number: 20200010539
    Abstract: The present invention relates to multifunctional protein molecules comprising decorin and uses thereof. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody and methods of their production and uses thereof.
    Type: Application
    Filed: June 28, 2019
    Publication date: January 9, 2020
    Inventor: Gregory T. Bleck
  • Veterinary decorin compositions and use thereof
    Patent number: 10137168
    Abstract: The present invention relates to veterinary decorin compositions and methods of their production.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: November 27, 2018
    Assignee: CATALENT PHARMA SOLUTIONS, LLC
    Inventor: Gregory T. Bleck
  • Fusion antibodies
    Patent number: 9541547
    Abstract: The present invention provides novel antibodies. In particular, the present invention provides fusion antibodies comprising antibody heavy and light chain fusions. The present invention further provides multivalent antibodies comprising multiple fusion antibody chains. The present invention further provides methods of generating splice resistant antibody genes.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: January 10, 2017
    Assignee: CATALENT PHARMA SOLUTIONS, INC.
    Inventors: Gregory T. Bleck, Dona York, Ian Collins
  • Nucleic acids encoding rage fusion proteins
    Patent number: 9399668
    Abstract: The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycatio? endproducts receptor (RAGE).
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: July 26, 2016
    Assignee: GALACTICA PHARMACEUTICALS, INC.
    Inventors: Gregory T. Bleck, David M. Hilbert
  • Nucleic acids encoding rage fusion proteins
    Publication number: 20150368315
    Abstract: The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycation endproducts receptor (RAGE).
    Type: Application
    Filed: May 22, 2015
    Publication date: December 24, 2015
    Applicant: GALACTICA PHARMACEUTICALS, INC.
    Inventors: Gregory T. BLECK, David M. HILBERT
  • Methods of treatment using rage fusion proteins
    Patent number: 9066927
    Abstract: The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycatio? endproducts receptor (RAGE).
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: June 30, 2015
    Assignee: GALACTICA PHARMACEUTICALS, INC.
    Inventors: Gregory T. Bleck, David M. Hilbert
  • VETERINARY DECORIN COMPOSITIONS AND USE THEREOF
    Publication number: 20140315806
    Abstract: The present invention relates to veterinary decorin compositions and methods of their production.
    Type: Application
    Filed: April 22, 2014
    Publication date: October 23, 2014
    Applicant: CATALENT PHARMA SOLUTIONS, LLC
    Inventor: Gregory T. Bleck
  • RAGE Fusion Protein Compositions And Methods Of Use
    Publication number: 20130142792
    Abstract: Disclosed are fusion proteins comprising a RAGE polypeptide, wherein the RAGE polypeptide comprises a fragment of a mammalian wild type RAGE peptide and at least one point mutation in the RAGE polypeptide portion of the fusion protein relative to the wild type RAGE peptide. The point mutation may remove and/or alter a glycosylation site or an enzyme cleavage site. Also disclosed are nucleic acids encoding such proteins as well as methods of using such proteins for treating RAGE-mediated pathologies.
    Type: Application
    Filed: October 19, 2010
    Publication date: June 6, 2013
    Inventors: Jeffrey C. Webster, Gregory T. Bleck, Madan Katragadda, Manoj Rajadhyaksha, Bernard N. Violand, Jo-Ann Wentland, Linda Marie Rothlein
  • Rage fusion proteins
    Patent number: 8398977
    Abstract: The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycation endproducts receptor (RAGE).
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: March 19, 2013
    Assignee: Galactica Pharmaceuticals, Inc.
    Inventors: Gregory T. Bleck, David M. Hilbert
  • RAGE FUSION PROTEINS
    Publication number: 20100291081
    Abstract: The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycation endproducts receptor (RAGE).
    Type: Application
    Filed: June 13, 2008
    Publication date: November 18, 2010
    Applicant: Galactica Pharmaceuticals
    Inventors: Gregory T. Bleck, David M. Hilbert
  • FUSION ANTIBODIES
    Publication number: 20100227394
    Abstract: The present invention provides novel antibodies. In particular, the present invention provides fusion antibodies comprising antibody heavy and light chain fusions. The present invention further provides multivalent antibodies comprising multiple fusion antibody chains. The present invention further provides methods of generating splice resistant antibody genes.
    Type: Application
    Filed: March 9, 2010
    Publication date: September 9, 2010
    Applicant: CATALENT PHARMA SOLUTIONS, INC.
    Inventors: Gregory T. Bleck, Dona York, Ian Collins
  • Fusion antibodies
    Patent number: 7696322
    Abstract: The present invention provides novel antibodies. In particular, the present invention provides fusion antibodies comprising antibody heavy and light chain fusions. The present invention further provides multivalent antibodies comprising multiple fusion antibody chains. The present invention further provides methods of generating splice resistant antibody genes.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: April 13, 2010
    Assignee: Catalent Pharma Solutions, Inc.
    Inventors: Gregory T. Bleck, Dona York, Ian Collins
  • Host Cells Containing Multiple Integrating Vectors
    Publication number: 20080286779
    Abstract: The present invention relates to the production of proteins in host cells, and more particularly to host cells containing multiple integrated copies of an integrating vector. Suitable integrating vectors for use in the present invention include retrovirus vectors, lentivirus vectors, transposon vectors, and adeno-associated virus vectors. Methods are provided in which the host cells are prepared by using the integrating vectors at a high multiplicity of infection. The host cells are useful for producing pharmaceutical proteins, variants of proteins for use in screening assays, and for direct use in high throughput screening.
    Type: Application
    Filed: October 30, 2007
    Publication date: November 20, 2008
    Applicant: Organization Name Catalent Pharma Solutions
    Inventors: Robert D. Bremmel, Linda U. Miller, Gregory T. Bleck